Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.53 |
| ▸ | BRD4 | O60885 | 5/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | PRLHR | P49683 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847158 | 0.89 | CREBBP (0.51) | CREBBPBRD4SYKGPR119GSK3B | |
| SCHEMBL2446674 | 0.89 | CREBBP (0.51) | CREBBPBRD4SYKGPR119GSK3B | |
| SCHEMBL2453164 | 0.87 | CREBBP (0.44) | CREBBPBRD4JAK3SYKGPR119 | |
| SCHEMBL2447276 | 0.85 | JAK3 (0.37) | CREBBPBRD4JAK3LCKSYK | |
| SCHEMBL2451064 | 0.84 | CREBBP (0.56) | CREBBPBRD4SYK | |
| SCHEMBL2447102 | 0.83 | CREBBP (0.44) | CREBBPBRD4JAK3SYKGPR119 | |
| SCHEMBL2447305 | 0.83 | CREBBP (0.53) | CREBBPBRD4SYKPRLHR | |
| SCHEMBL2449067 | 0.82 | CREBBP (0.61) | CREBBPBRD4JAK3SYK | |
| SCHEMBL2450016 | 0.82 | CREBBP (0.49) | CREBBPBRD4SYKGPR119PRLHR | |
| SCHEMBL2444488 | 0.81 | CREBBP (0.51) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | claimed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | claimed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | claimed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | CREBBP 646/4885BRD4 1537/4885JAK3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.